148 related articles for article (PubMed ID: 37740779)
21. Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.
Hayakawa Y; Tsuchiya K; Kurosaki M; Yasui Y; Kaneko S; Tanaka Y; Ishido S; Inada K; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Tamaki N; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Okamoto R; Izumi N
Invest New Drugs; 2022 Apr; 40(2):392-402. PubMed ID: 34586531
[TBL] [Abstract][Full Text] [Related]
22. Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma.
Kim HI; Lim J; Shim JH
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2069-2077. PubMed ID: 34459972
[TBL] [Abstract][Full Text] [Related]
23. The prognostic role of early tumor shrinkage in patients with hepatocellular carcinoma undergoing immunotherapy.
Müller L; Gairing SJ; Kloeckner R; Foerster F; Schleicher EM; Weinmann A; Mittler J; Stoehr F; Halfmann MC; Düber C; Galle PR; Hahn F
Cancer Imaging; 2022 Sep; 22(1):54. PubMed ID: 36153569
[TBL] [Abstract][Full Text] [Related]
24. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
Scheiner B; Pomej K; Kirstein MM; Hucke F; Finkelmeier F; Waidmann O; Himmelsbach V; Schulze K; von Felden J; Fründt TW; Stadler M; Heinzl H; Shmanko K; Spahn S; Radu P; Siebenhüner AR; Mertens JC; Rahbari NN; Kütting F; Waldschmidt DT; Ebert MP; Teufel A; De Dosso S; Pinato DJ; Pressiani T; Meischl T; Balcar L; Müller C; Mandorfer M; Reiberger T; Trauner M; Personeni N; Rimassa L; Bitzer M; Trojan J; Weinmann A; Wege H; Dufour JF; Peck-Radosavljevic M; Vogel A; Pinter M
J Hepatol; 2022 Feb; 76(2):353-363. PubMed ID: 34648895
[TBL] [Abstract][Full Text] [Related]
25. Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients.
Sun X; Mei J; Lin W; Yang Z; Peng W; Chen J; Zhang Y; Xu L; Chen M
BMC Cancer; 2021 Jul; 21(1):775. PubMed ID: 34218801
[TBL] [Abstract][Full Text] [Related]
26. Alpha-fetoprotein assessment for hepatocellular carcinoma after transarterial chemoembolization.
Tian M; Zhang X; Huang G; Fan W; Li J; Zhang Y
Abdom Radiol (NY); 2019 Oct; 44(10):3304-3311. PubMed ID: 31250181
[TBL] [Abstract][Full Text] [Related]
27. Response Evaluation and Survival Prediction Following PD-1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria.
Zhou M; Zhang C; Nie J; Sun Y; Xu Y; Wu F; Huang Y; Li S; Wang Y; Zhou Y; Zheng T
Front Oncol; 2021; 11():764189. PubMed ID: 34956885
[TBL] [Abstract][Full Text] [Related]
28. Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC.
Lewis S; Cedillo MA; Lee KM; Bane O; Hectors S; Ma W; Wang P; Stocker D; Morris DV; Pinato D; Sung M; Marron T; Schwartz M; Taouli B
Abdom Radiol (NY); 2022 Mar; 47(3):969-980. PubMed ID: 34964909
[TBL] [Abstract][Full Text] [Related]
29. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
Ronot M; Bouattour M; Wassermann J; Bruno O; Dreyer C; Larroque B; Castera L; Vilgrain V; Belghiti J; Raymond E; Faivre S
Oncologist; 2014 Apr; 19(4):394-402. PubMed ID: 24652387
[TBL] [Abstract][Full Text] [Related]
30. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
[TBL] [Abstract][Full Text] [Related]
31. The combination of a prolonged treatment time window and alpha-fetoprotein benefits the tumor response of hepatocellular carcinoma patients as evaluated by the imRECIST: a single-center, retrospective study.
Yin KL; Li M; Liao R; Shi ZR; Qiu JG; Lan X; Duan YX; Ye WT; Wu ZY; Du CY; Xiao H
J Gastrointest Oncol; 2023 Apr; 14(2):932-942. PubMed ID: 37201094
[TBL] [Abstract][Full Text] [Related]
32. The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy.
Xu Y; Yang Y; Li L; Ye F; Zhao X
Front Oncol; 2022; 12():905260. PubMed ID: 35686094
[TBL] [Abstract][Full Text] [Related]
33. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
Wang W; Bai W; Wang E; Zhao Y; Liu L; Yang M; Cai H; Xia D; Zhang L; Niu J; Yin Z; Zhang Z; Fan D; Xia J; Han G
Int J Cancer; 2017 Jan; 140(2):390-399. PubMed ID: 27681592
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of PD-1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study.
Yao J; Zhu X; Wu Z; Wei Q; Cai Y; Zheng Y; Hu X; Hu H; Zhang X; Pan H; Zhong X; Han W
Cancer Med; 2022 Oct; 11(19):3612-3622. PubMed ID: 35403359
[TBL] [Abstract][Full Text] [Related]
35. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
Takada J; Hidaka H; Nakazawa T; Kondo M; Numata K; Tanaka K; Matsunaga K; Okuse C; Kobayashi S; Morimoto M; Ohkawa S; Koizumi W
BMC Res Notes; 2015 Oct; 8():609. PubMed ID: 26502722
[TBL] [Abstract][Full Text] [Related]
36. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein.
Kinami T; Amioka K; Kawaoka T; Uchikawa S; Yamasaki S; Kosaka M; Johira Y; Yano S; Naruto K; Ando Y; Yamaoka K; Fujii Y; Fujino H; Nakahara T; Ono A; Murakami E; Okamoto W; Yamauchi M; Miki D; Tsuge M; Imamura M; Aikata H; Oka S
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190231
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
Lee YK; Kim SU; Kim DY; Ahn SH; Lee KH; Lee DY; Han KH; Chon CY; Park JY
BMC Cancer; 2013 Jan; 13():5. PubMed ID: 23282286
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma.
Lee JS; Chon YE; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kang W; Choi MS; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Kim HY; Kim TH; Yoo K; Ha Y; Kim MN; Lee JH; Hwang SG; Kim SS; Cho HJ; Cheong JY; Cho SW; Park SH; Heo NY; Hong YM; Yoon KT; Cho M; Park JG; Kang MK; Park SY; Kweon YO; Tak WY; Jang SY; Sinn DH; Kim SU;
Yonsei Med J; 2021 Jan; 62(1):12-20. PubMed ID: 33381930
[TBL] [Abstract][Full Text] [Related]
40. Propensity Score Matching Analysis of Changes in Alpha-Fetoprotein Levels after Combined Radiotherapy and Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Jeong Y; Yoon SM; Han S; Shim JH; Kim KM; Lim YS; Lee HC; Kim SY; Park JH; Lee SW; Ahn SD; Choi EK; Kim JH
PLoS One; 2015; 10(8):e0135298. PubMed ID: 26252472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]